Quibim secured €47.6 million in Series A funding to enhance its precision medicine offerings using image biomarkers and AI, positioning itself for significant global growth.
Target Information
Quibim, a pioneering company in the field of precision medicine, has successfully closed a Series A funding round amounting to €47.6 million. This investment is designated to enhance Quibim's portfolio of products and expedite its global commercial growth. The company is focused on utilizing image biomarkers and artificial intelligence to revolutionize healthcare, providing innovative solutions that improve patient outcomes.
Founded with a vision to transform the diagnostic landscape, Quibim's approach combines advanced image analysis with machine learning technologies. The firm's dedication to precision medicine positions it favorably as a significant player in the healthcare technology sector.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The healthcare technology industry in Spain has witnessed substantial growth, especially in precision medicine, driven by increased investment and technolog
Similar Deals
Asabys Partners and Buenavista Equity Partners → Quibim
2025
Asabys, Buenavista, GoHub Ventures, UI Investissement, Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures, Leadwind, individual investors
invested in
Quibim
in 2025
in a Series A deal
Disclosed details
Transaction Size: $51M